Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093603669> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2093603669 endingPage "470" @default.
- W2093603669 startingPage "463" @default.
- W2093603669 abstract "There is increasing interest in the clinical utility and pharmacoeconomic benefits of continuous infusion (CI) therapy with β-lactam antibiotics because this form of therapy may be as efficacious as and less costly than intermittenl infusion (II) therapy. We investigated the efficacy, pharmacokinetics, and pharmacocconomics of CI cefuroxime therapy in adult patients with a primary diagnosis of community-acquired pneumonia (CAP) who were admitted to a 800-bed community teaching hospital. Twenty-five patients with CAP who received 750 or l500 mg of cefuroxime per day by CI were compared with 25 patients given 750 mg of cefuroxime three times daily by II. Clinical cure or improvement at the end of the course of intravenous therapy and 30 clays later occurred in 23/24 and 21/22 evaluable patients in the II and CI groups, respectively. Steady-slate serum cefuroxime concentrations in CI patients were 13.25 ± 6.29 μg/mL. These concentrations are more; than two to lour limes the MIC90 values of the bacterial pathogens typically associated with CAP. The mean (± SD) total amount of intravenous drug used (II group, 8021 ± 3444 mg; CI group, 5953 ± 3210 mg; P = .04) and cost of the drug, labor, and supplies (II group, $83.85 ± $34.82; CI group, $63.64 ± $30.95; P = .04) were less in the CI group. Duration of inpalienl antimicrobial therapy and length of hospital stay tended to be shorter in the CI group, by 14.7 and 11.6 hours, respectively (P = not significant). The duration of outpatient oral therapy was longer in the CI group (P = .05). Consequently, there was a tendency toward shorter duration of inpalienl therapy and longer duration of outpatient therapy in the CI group. These data support CI celuroxime therapy as a pharmacody-namically sound and pharmacoeconomically beneficial alternative to II therapy in the treatment of CAP. However, randomized controlled trials may be warranted to verify the equivalence of efficacy between treatment regimens." @default.
- W2093603669 created "2016-06-24" @default.
- W2093603669 creator A5045167689 @default.
- W2093603669 creator A5058850371 @default.
- W2093603669 creator A5082374820 @default.
- W2093603669 creator A5090740872 @default.
- W2093603669 date "1998-12-01" @default.
- W2093603669 modified "2023-10-18" @default.
- W2093603669 title "CONTINUOUS VS. INTERMITTENT INFUSION OF CEFUROXIME FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA" @default.
- W2093603669 doi "https://doi.org/10.1097/00019048-199812000-00007" @default.
- W2093603669 hasPublicationYear "1998" @default.
- W2093603669 type Work @default.
- W2093603669 sameAs 2093603669 @default.
- W2093603669 citedByCount "34" @default.
- W2093603669 countsByYear W20936036692013 @default.
- W2093603669 countsByYear W20936036692015 @default.
- W2093603669 countsByYear W20936036692016 @default.
- W2093603669 countsByYear W20936036692018 @default.
- W2093603669 countsByYear W20936036692019 @default.
- W2093603669 countsByYear W20936036692020 @default.
- W2093603669 countsByYear W20936036692023 @default.
- W2093603669 crossrefType "journal-article" @default.
- W2093603669 hasAuthorship W2093603669A5045167689 @default.
- W2093603669 hasAuthorship W2093603669A5058850371 @default.
- W2093603669 hasAuthorship W2093603669A5082374820 @default.
- W2093603669 hasAuthorship W2093603669A5090740872 @default.
- W2093603669 hasBestOaLocation W20936036691 @default.
- W2093603669 hasConcept C112705442 @default.
- W2093603669 hasConcept C126322002 @default.
- W2093603669 hasConcept C141071460 @default.
- W2093603669 hasConcept C2776102371 @default.
- W2093603669 hasConcept C2777514703 @default.
- W2093603669 hasConcept C2777914695 @default.
- W2093603669 hasConcept C2780608335 @default.
- W2093603669 hasConcept C42219234 @default.
- W2093603669 hasConcept C501593827 @default.
- W2093603669 hasConcept C71924100 @default.
- W2093603669 hasConcept C86803240 @default.
- W2093603669 hasConcept C89423630 @default.
- W2093603669 hasConceptScore W2093603669C112705442 @default.
- W2093603669 hasConceptScore W2093603669C126322002 @default.
- W2093603669 hasConceptScore W2093603669C141071460 @default.
- W2093603669 hasConceptScore W2093603669C2776102371 @default.
- W2093603669 hasConceptScore W2093603669C2777514703 @default.
- W2093603669 hasConceptScore W2093603669C2777914695 @default.
- W2093603669 hasConceptScore W2093603669C2780608335 @default.
- W2093603669 hasConceptScore W2093603669C42219234 @default.
- W2093603669 hasConceptScore W2093603669C501593827 @default.
- W2093603669 hasConceptScore W2093603669C71924100 @default.
- W2093603669 hasConceptScore W2093603669C86803240 @default.
- W2093603669 hasConceptScore W2093603669C89423630 @default.
- W2093603669 hasIssue "9" @default.
- W2093603669 hasLocation W20936036691 @default.
- W2093603669 hasLocation W20936036692 @default.
- W2093603669 hasOpenAccess W2093603669 @default.
- W2093603669 hasPrimaryLocation W20936036691 @default.
- W2093603669 hasRelatedWork W2044490746 @default.
- W2093603669 hasRelatedWork W2093603669 @default.
- W2093603669 hasRelatedWork W2140466477 @default.
- W2093603669 hasRelatedWork W2367465921 @default.
- W2093603669 hasRelatedWork W2374956397 @default.
- W2093603669 hasRelatedWork W2382293659 @default.
- W2093603669 hasRelatedWork W97342277 @default.
- W2093603669 hasRelatedWork W97493058 @default.
- W2093603669 hasRelatedWork W2396790870 @default.
- W2093603669 hasRelatedWork W2806104956 @default.
- W2093603669 hasVolume "7" @default.
- W2093603669 isParatext "false" @default.
- W2093603669 isRetracted "false" @default.
- W2093603669 magId "2093603669" @default.
- W2093603669 workType "article" @default.